ClinicalTrials.gg
CompletedNCT03363893Updated Jun 23, 2026Results posted

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

A Phase 1/2 interventional study of CT7001 and Fulvestrant in Advanced Solid Malignancies, sponsored by Carrick Therapeutics Limited. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Carrick Therapeutics Limited · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

Read the detailed description

Module 1 comprises two sequential parts:

  • Part A: First-in-human (FiH) dose escalation investigating the safety and tolerability of CT7001 to identify the minimum biologically active dose (MBAD) and maximum tolerated dose (MTD). Part A also includes a cohort expansion for breast cancer participants only: this includes sequential tumour biopsies for evaluation of pharmacokinetic (PK), pharmacodynamic (PD) and tumour responses. The module is completed.
  • Part B: To refine the safety, tolerability, and PK and PD profiles of CT7001 monotherapy in participants with advanced solid malignancies from up to four tumour- specific cohorts, which may include, but is not limited to, triple-negative breast cancer, ovarian cancer, small-cell lung cancer and prostate cancer.

    • Part B, Cohort 1, Triple-Negative Breast Cancer (M1B-1 TNBC) treated with CT7001 as monotherapy. The module is completed.
    • Part B, Cohort 2, Prostate Cancer (M1B-2 CRPC) treated with CT7001 as monotherapy. The module is completed.
  • Module 2 is a Phase Ib/II, 3-part safety and efficacy study in participants with hormone- receptor positive (HR+ve) and human epidermal growth factor-2 negative (HER2-ve) breast cancer. This module includes dosing CT7001 in combination with fulvestrant. Module 2 was planned to comprise of 3 parts; Part A (open-label, single-arm, ascending dose study), Part B (double blinded, randomised, placebo-controlled study) and Part C (crossover from Part B). However, only Module 2 Part A was initiated and completed. Therefore, further sections of this record only reflect Module 2 Part A information.
  • Module 4 is a study investigating the effect of food on the PK of CT7001 monotherapy in participants with advanced solid malignancies. The module is completed.
  • Module 6 was planned as a Phase 1 study to explore the tolerability of, and the total and peak exposure of, an enteric capsule formulation of CT7001 [CT7001(EC)], when given as monotherapy to patients with advanced solid malignancies. Module 6 was not initiated.
02

Conditions studied

  • Advanced Solid Malignancies

Browse trials for

Keywords

  • Neoplasms
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 124 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Carrick Therapeutics Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Core Inclusion Criteria:

  1. performance status 0 or 1 with no deterioration over the previous 2 weeks
  2. Estimated of greater than 12 weeks
  3. Ability to swallow and retain oral medication
  4. Women either of non- or of childbearing potential willing to practice effective for the duration of the study and for 6 months (Module 1, Module 4) and 24 months (Module 2) after the last dose of CT7001
  5. Sexually active male patients must be willing to use condoms with all sexual partners for the duration of the study and for 3 months after the last dose of CT7001.
  6. Provision of signed and dated, written

Core Exclusion Criteria:

  1. Any other that has been active or treated within the past 3 years, with the exception of cervical intraepithelial neoplasia and non-melanoma skin cancer
  2. Any unresolved toxicity (except alopecia) from prior therapy of ≥ Grade 2
  3. Spinal cord compression or , unless asymptomatic, stable, and not requiring for at least 4 weeks before the first dose of product (IP)
  4. nausea and vomiting, chronic gastrointestinal (GI) disease or previous significant bowel resection, with sequelae that would preclude adequate absorption of CT7001
  5. Uncontrolled seizures
  6. Active infection requiring systemic antibiotic, antifungal, or antiviral medication
  7. Severe or uncontrolled medical condition or psychiatric condition
  8. Active bleeding diatheses
  9. Renal transplant
  10. Known , , or infection
  11. Breastfeeding or pregnancy
  12. Receipt of systemic cytotoxic treatment for the malignancy within 28 days or ≤ 5 half-lives, whichever is shorter before the first dose of IP
  13. Receipt of non-cytotoxic treatment for the malignancy within 5 half-lives of the drug before the first dose of IP
  14. Receipt of corticosteroids (at a dose > 10 mg prednisone/day or equivalent) within 14 days before the first dose of IP
  15. Receipt of any small-molecule investigational medicinal product (IMP) within 28 days or ≤ 5 half-lives, whichever is shorter before the first dose of IP
  16. Receipt of any biological IMP (e.g., immune checkpoint blockers, antibodies, nanoparticles) within 42 days before the first dose of IP
  17. Receipt of St John's Wort within 21 days before the first dose of IP or of another concomitant medication, herbal supplement, or food that is a strong inhibitor or inducer of , CYP2C19, CYP2D6, or P-glycoprotein (PGP) activity within 14 days before the first dose of CT7001
  18. Receipt of a blood transfusion (blood or blood products) within 14 days before the first dose of IP
  19. Known to CT7001 or any of the product
  20. Impaired hepatic or renal function as demonstrated by any of the following laboratory values:

    1. Albumin \< 30 g/L
    2. (AST) or alanine aminotransferase (ALT) > 2.5 × the (ULN)
    3. > 5.0 × ULN for patients with liver
    4. Total > 1.5 × ULN
    5. Serum creatinine > 1.5 × ULN
  21. Liver function deteriorating in a manner that would likely make the participant meet the AST, ALT, or bilirubin levels specified above at the time of the first dose of IP
  22. Other evidence of impaired hepatic synthesis function
  23. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    1. (ANC) \< 1.5 × 10\^9/L
    2. count \< 100 × 10\^9/L
    3. \< 90 g/L
  24. Persistent (> 4 weeks) severe pancytopenia due to previous therapy rather than to disease (ANC \< 0.5 × 10\^9/L or platelets \< 50 x 10\^9/L)
  25. Cardiac dysfunction (defined as myocardial infarction within 6 months of study entry, Class II/III/IV heart failure, unstable angina, unstable cardiac arrhythmias, or \< 55 percent)
  26. Mean resting corrected for heart rate by the Fridericia formula (QTcF) > 470 msec obtained from 3 (ECGs) obtained within 5 minutes of each other prior to the first dose
  27. Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG (e.g., complete left bundle branch block, third degree heart block). Controlled atrial fibrillation (AF) is permitted
  28. Any factor that increases the risk of QTc prolongation or of arrhythmic events (e.g., heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40 years of age)
  29. In the opinion of the Investigator, unlikely to comply with study procedures, restrictions, or requirements
  30. A history of haemolytic anaemia or marrow aplasia
  31. Has received a live-virus vaccination within 28 days or less of planned treatment start

Additional Module 1A Inclusion Criteria:

  1. Histological, radiological or cytological confirmation of an advanced non-haematological malignancy not considered to be appropriate for further standard treatment
  2. Module 1A cohort only : at least one tumour suitable for repeat biopsy

Additional Module 1A Exclusion Criteria:

1. (INR) ≥1.5

Additional Module 1B Inclusion Criteria

  1. Histological or cytological confirmation of metastasis or locally advanced tumour
  2. At least one line of systemic anti-cancer therapy
  3. Disease measurable by v1.1

Additional Module 1B-1 (TNBC Expansion) Inclusion Criteria:

  1. -confirmed carcinoma of breast not expressing oestrogen receptor (ER) or progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 ()
  2. Documented disease progression on or within 6 months of most recent cytotoxic prior cytotoxic chemotherapy
  3. Disease measurable by RECIST v1.1
  4. Must have received at least one cytotoxic chemotherapy for metastatic/locally advanced disease

Additional Module 1B-1 (TNBC Expansion) Exclusion Criteria:

  1. No more than three lines of cytotoxic chemotherapy for metastatic/locally advanced disease
  2. No advanced, symptomatic visceral metastases
  3. No known symptomatic central nervous system (CNS) metastases, carcinomatous meningitis or
  4. Prior exposure to CT7001
  5. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Carrick employees directly involved in the conduct of the trial

Additional Module 2A Inclusion Criteria:

  1. Women only
  2. Pre- or peri-menopausal women must have initiated LHRHa at least 28 days prior to first dose of CT7001/placebo
  3. Histologically-confirmed, metastatic or locally advanced, ER+ve and/or PGR+ve and HER2-ve breast cancer
  4. Disease measurable by RECIST v1.1
  5. Documented objective disease progression while on, or within 6 months after the end of, the most recent therapy
  6. Must have received an aromatase inhibitor together with a CDK4/6 inhibitor in the same for locally advanced or metastatic disease or for treatment of early breast cancer if the disease-free interval was \<12 months.
  7. Ability to receive intramuscular injections.

Additional Module 2A Exclusion Criteria:

  1. Prior therapy with fulvestrant
  2. More than 2 lines of endocrine treatment for locally advanced or metastatic disease
  3. Prior treatment with more than one line of cytotoxic chemotherapy for locally advanced or metastatic breast cancer.
  4. Patients with liver metastasis will be limited to approximately 30-40% of the enrolled patients. l
  5. Known hypersensitivity to CT7001, fulvestrant or any excipient of the investigational products
  6. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Carrick employees directly involved in the conduct of the trial

Additional Module 4 Inclusion Criteria:

  1. Patients must be able to eat a high-fat meal, as provided by the study site, within a 30-minute period
  2. Histological, radiological or cytological confirmation of an advanced non-haematological malignancy not considered to be appropriate for further standard treatment

Additional Module 4 Exclusion Criteria:

1. Patients who were unable to fast for at least 10 hours

Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Module 1 Part A Multiple ascending dose cohort and Paired Biopsy Breast Cancer Expansion Cohort

    Module 1 Part A Multiple ascending dose cohort: Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). Following completion of the dose escalation part of Module 1A, participants to receive safe, tolerable and MBAD of CT7001 for the paired biopsy expansion cohort. Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort: Participants with locally advanced or metastatic breast cancer will receive CT7001 (samuraciclib) as oral monotherapy at the minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D).

    Drug: CT7001

  • Experimental
    Module 1 Part B-1 Triple-negative breast cancer (TNBC) Expansion

    Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.

    Drug: CT7001

  • Experimental
    Module 1 Part B-2 Castrate resistant prostate Cancer (CRPC) Expansion

    Participants with castrate resistant prostate cancer will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.

    Drug: CT7001

  • Experimental
    Module 2 Part A

    Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) at the dose, frequency and schedule recommended from Module 1 part A and will receive Fulvestrant solution in pre-filled syringe for intramuscular (IM) injection

    Drug: CT7001 · Drug: Fulvestrant

  • Experimental
    Module 4

    Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.

    Drug: CT7001

Interventions

  • DrugCT7001

    Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression

    Also known as: Samuraciclib

  • Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.

    Also known as: Faslodex

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)

    Treatment-emergent adverse events (TEAEs) are defined as those AEs which occur from Cycle 0 Day 1/Cycle 1 Day 1 of the study module to 28 days after the last dose of CT7001 in a module. Results reported below for Participants with one or more related TEAEs.

    Time frame: Screening to end of study (28-35 calendar days after end of treatment). End of treatment at disease progression, unacceptable toxicity or withdrawal of consent. Average time on study 142.6 days (range 9 - 1135 days)

Secondary outcomes

  1. Maximum Plasma Concentration of CT7001 (Cmax)

    Cmax is the maximum observed plasma concentration of CT7001 following oral dosing.

    Time frame: After the first dose and during the dosing period (from the time of dose administration to 24 hours) for Module 1A cohorts. Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 24, 48, 72, 120 and 168 hours post dose for Module 4 Cohorts.

  2. Area Under the Curve (AUC)

    Area under the plasma concentration-time curve representing the total drug exposure over time.

    Time frame: After the first dose and during the dosing period (from the time of dose administration to 24 hours) for Module 1A. Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 24, 48, 72, 120 and 168 hours post dose for Module 4 Cohorts.

  3. Mean Trough Plasma Pharmacokinetic Concentrations for CT7001

    Mean Trough Plasma Pharmacokinetic Concentrations is the lowest concentration of a drug in the bloodstream during a dosing interval. Timeframe: On study sampling: M1A - Day 1, 8, 15, 22, 29, 43, 50, every 21 days thereafter and EOT. M1B-1 and M1B-2: Day1, 8, 22, every 21 days thereafter and EOT. M2A: Day1, 15, 29, 57, every 56 days thereafter and EOT. M4: Day 1, 8, 15, 22, 29, 36, every 21 days thereafter and EOT.

    Time frame: From enrolment (Day 1) through to disease progression, unacceptable toxicity or withdrawal of consent, whichever came first (EOT). Assessed up to 1135 days. On study pre-dose sampling for all modules (see outcome measure description).

  4. Mean Trough Plasma Pharmacokinetic Concentrations for Fulvestrant (Module 2A)

    Mean trough plasma PK concentrations refer to the lowest concentration of a drug in the bloodstream during a dosing interval.

    Time frame: From enrolment through to disease progression, unacceptable toxicity or withdrawal of consent, whichever came first (EOT). Pre-dose sampling at Day 1, 15, 29, 57 and every 56 days thereafter and EOT. Assessed up to 848 days.

  5. Anti-tumour Activity According to RECIST v1.1-Best Objective Response

    Antitumour activity endpoints were analysed using the evaluable for Response population (any patient with at least one post baseline RECIST assessment). Best objective response is defined as the best response recorded from the start of study treatment to the end of treatment, including any assessments for confirmation after the end of treatment. Percentage of participants with each response calculated was based on the total number of participants with a baseline RECIST assessment. Timeframe: Scan frequency - Modules 1A and 4 (every 6 weeks); Modules 1B-1 and 2A (every 8 weeks first year, every 12 weeks thereafter); Module 1B-2 (every 8 weeks for the 6 months, every 12 weeks thereafter).

    Time frame: From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1135 days (162 weeks). Frequency in outcome measure description.

  6. Anti-tumour Activity According to RECIST v1.1-Progression Free Survival

    Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Progression free survival is defined as the time from start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant had withdrawn from therapy or had received another anti-cancer therapy prior to progression. Participants who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.

    Time frame: From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first. Modules 1B-1 and 2A: every 8 weeks first year, every 12 weeks thereafter) assessed up to 848 days (121 weeks).

  7. Anti-tumour Activity According to RECIST v1.1-Clinical Benefit Rate (CBR)

    Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Clinical Benefit Rate (CBR) is defined as the percentage of subjects with a confirmed objective response of complete response or partial response, or stabilisation of disease for at least 24 weeks.

    Time frame: From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first. Module 2A: every 8 weeks first year, every 12 weeks thereafter) assessed up to 848 days (121 weeks).

07

Results

Posted Jun 23, 2026

Participant flow

This study recruited participants at least 18 years of age with histological or cytological confirmation of an advanced malignancy, with an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 and an estimated life expectancy greater than 12 weeks.

Participant flow — Overall Study
MilestoneModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4-120 mg OD Fed-Fasted (Sequence 1)Module 4 120 mg OD Fasted-Fed (Sequence 2)Module 4 360 mg OD Fed-Fasted (Sequence 3)Module 4 360 mg OD Fasted-Fast (Sequence 4)
Started676685623116254443
Completed676685623116254443
Not completed000000000000000

Outcome measures

PrimaryTreatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)

Treatment-emergent adverse events (TEAEs) are defined as those AEs which occur from Cycle 0 Day 1/Cycle 1 Day 1 of the study module to 28 days after the last dose of CT7001 in a module. Results reported below for Participants with one or more related TEAEs.

Time frame:
Screening to end of study (28-35 calendar days after end of treatment). End of treatment at disease progression, unacceptable toxicity or withdrawal of consent. Average time on study 142.6 days (range 9 - 1135 days)
Reported as:
Count of participants · Participants
Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)
ParticipantsModule 1 PartA-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240mg ODModule 1 Part A-Cohort 3 480mg ODModule 1 Part A-Cohort 4 360mg ODModule 1 Part A-Cohort 5 180mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2A 240 mg ODModule 2A 360 mg ODModule 4 120 mg OD FedModule 4 120mg OD FastedModule 4 360 mg OD FedModule 4 360mg OD FastedModule 4 240 mg OD Continuous DosingModule 4 360 mg OD Continuous Dosing
Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)67668562211624055487
SecondaryMaximum Plasma Concentration of CT7001 (Cmax)

Cmax is the maximum observed plasma concentration of CT7001 following oral dosing.

Time frame:
After the first dose and during the dosing period (from the time of dose administration to 24 hours) for Module 1A cohorts. Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 24, 48, 72, 120 and 168 hours post dose for Module 4 Cohorts.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration of CT7001 (Cmax)
ng/mLModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360mg ODModule 1 Part A-Cohort 5 180mg BIDModule 4 120 mg OD FedModule 4 120 mg OD FastedModule 4 360 mg OD FedModule 4 360 mg OD Fasted
Maximum Plasma Concentration of CT7001 (Cmax)89.15 ± 106.9201.4 ± 22.25172.8 ± NA270.2 ± 45.69233.3 ± 28.7519.21 ± 149.163.77 ± 108.8138.8 ± 19.72176.1 ± 63.91
SecondaryArea Under the Curve (AUC)

Area under the plasma concentration-time curve representing the total drug exposure over time.

Time frame:
After the first dose and during the dosing period (from the time of dose administration to 24 hours) for Module 1A. Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 24, 48, 72, 120 and 168 hours post dose for Module 4 Cohorts.
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve (AUC)
h*ng/mLModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360mg ODModule 1 Part A-Cohort 5 180mg BIDModule 4-120 mg OD FedModule 4 120 mg OD FastedModule 4 360 mg OD FedModule 4 360 mg OD Fasted
Area Under the Curve (AUC)802.9 ± 83.831926 ± 18.752506 ± NA2791 ± 27.631377 ± 15.21785.3 ± 14.26694.9 ± 55.932696 ± 41.382545 ± 66.10
SecondaryMean Trough Plasma Pharmacokinetic Concentrations for CT7001

Mean Trough Plasma Pharmacokinetic Concentrations is the lowest concentration of a drug in the bloodstream during a dosing interval. Timeframe: On study sampling: M1A - Day 1, 8, 15, 22, 29, 43, 50, every 21 days thereafter and EOT. M1B-1 and M1B-2: Day1, 8, 22, every 21 days thereafter and EOT. M2A: Day1, 15, 29, 57, every 56 days thereafter and EOT. M4: Day 1, 8, 15, 22, 29, 36, every 21 days thereafter and EOT.

Time frame:
From enrolment (Day 1) through to disease progression, unacceptable toxicity or withdrawal of consent, whichever came first (EOT). Assessed up to 1135 days. On study pre-dose sampling for all modules (see outcome measure description).
Reported as:
Geometric mean · ng/mL
Mean Trough Plasma Pharmacokinetic Concentrations for CT7001
ng/mLModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4 240 mg OD (Continuous Dosing Phase)Module 4 360 mg OD (Continuous Dosing Phase)
Mean Trough Plasma Pharmacokinetic Concentrations for CT700116.12 ± 71.1744.60 ± 32.0560.60 ± NA63.40 ± 47.8955.91 ± 78.9039.22 ± 41.4841.56 ± 47.94NA ± NA68.97 ± 69.247.87 ± 41.4434.26 ± 138.3
SecondaryMean Trough Plasma Pharmacokinetic Concentrations for Fulvestrant (Module 2A)

Mean trough plasma PK concentrations refer to the lowest concentration of a drug in the bloodstream during a dosing interval.

Time frame:
From enrolment through to disease progression, unacceptable toxicity or withdrawal of consent, whichever came first (EOT). Pre-dose sampling at Day 1, 15, 29, 57 and every 56 days thereafter and EOT. Assessed up to 848 days.
Reported as:
Geometric mean · ng/mL
Mean Trough Plasma Pharmacokinetic Concentrations for Fulvestrant (Module 2A)
ng/mLModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)
Mean Trough Plasma Pharmacokinetic Concentrations for Fulvestrant (Module 2A)12.65 ± 13.8812.47 ± 36.96
SecondaryAnti-tumour Activity According to RECIST v1.1-Best Objective Response

Antitumour activity endpoints were analysed using the evaluable for Response population (any patient with at least one post baseline RECIST assessment). Best objective response is defined as the best response recorded from the start of study treatment to the end of treatment, including any assessments for confirmation after the end of treatment. Percentage of participants with each response calculated was based on the total number of participants with a baseline RECIST assessment. Timeframe: Scan frequency - Modules 1A and 4 (every 6 weeks); Modules 1B-1 and 2A (every 8 weeks first year, every 12 weeks thereafter); Module 1B-2 (every 8 weeks for the 6 months, every 12 weeks thereafter).

Time frame:
From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1135 days (162 weeks). Frequency in outcome measure description.
Reported as:
Number · participants
Anti-tumour Activity According to RECIST v1.1-Best Objective Response
participantsModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360mg ODModule 1 Part A-Cohort 5 180mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part ACT7001 240 mg OD +Fulvestrant (Cohort 1)Module 2 Part ACT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4-120mg OD FedModule 4 120mg OD FastedModule 4 360mg OD FedModule 4 360mg OD FastedModule 4 240 mg OD Continuous DosingModule 4 360 mg OD Continuous Dosing
Complete response00000000000————00
Partial response00000101012————00
Stable disease2304423115310————54
Progressive disease42223228527————33
Not evaluable00000003100————00
SecondaryAnti-tumour Activity According to RECIST v1.1-Progression Free Survival

Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Progression free survival is defined as the time from start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant had withdrawn from therapy or had received another anti-cancer therapy prior to progression. Participants who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment.

Time frame:
From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first. Modules 1B-1 and 2A: every 8 weeks first year, every 12 weeks thereafter) assessed up to 848 days (121 weeks).
Reported as:
Median · days
Anti-tumour Activity According to RECIST v1.1-Progression Free Survival
daysModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion.Module 2 Part ACT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part ACT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4 120 mg OD FedModule 4 120mg OD FastedModule 4 360 mg OD FedModule 4 360mg OD FastedModule 4 240 mg OD Continuous DosingModule 4 360 mg OD Continuous Dosing
Anti-tumour Activity According to RECIST v1.1-Progression Free SurvivalNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)72 (56 to 113)NA (NA to NA)107 (51 to NA)114 (56 to 421)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryAnti-tumour Activity According to RECIST v1.1-Clinical Benefit Rate (CBR)

Antitumour activity endpoints were analysed using the evaluable for Response population based on RECIST assessment. Clinical Benefit Rate (CBR) is defined as the percentage of subjects with a confirmed objective response of complete response or partial response, or stabilisation of disease for at least 24 weeks.

Time frame:
From enrolment (Day 1) until the date of first documented progression or date of death from any cause, whichever came first. Module 2A: every 8 weeks first year, every 12 weeks thereafter) assessed up to 848 days (121 weeks).
Reported as:
Number · percentage of subjects
Anti-tumour Activity According to RECIST v1.1-Clinical Benefit Rate (CBR)
percentage of subjectsModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240mg ODModule 1 Part A-Cohort 3 480mg ODModule 1 Part A-Cohort 4 360mg ODModule 1 Part A-Cohort 5 180mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part ACT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part ACT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4 120mg OD FedModule 4 120mg OD FastedModule 4 360mg OD FedModule 4 360mg OD FastedModule 4 240mg OD Continuous DosingModule 4 360mg OD Continous Dosing
Anti-tumour Activity According to RECIST v1.1-Clinical Benefit Rate (CBR)NANANANANANANANANA16.742.1NANANANANANA

Adverse events

Collected over SAEs from consent, AEs from Day 1 to end of study (EOS). EOS (up to 35 days after EOT). EOT is date of first documented disease progression, unacceptable toxicity or withdrawal of consent, whichever came first. Assessed up to 1198 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Module 1 Part A-Cohort 1 120mg OD1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Module 1 Part A-Cohort 2 240mg OD1/12 (8.3%)4/12 (33.3%)12/12 (100%)
Module 1 Part A-Cohort 3 480mg OD0/6 (0%)1/6 (16.7%)6/6 (100%)
Module 1 Part A-Cohort 4 360mg OD0/12 (0%)3/12 (25%)12/12 (100%)
Module 1 Part A-Cohort 5 180mg BID0/8 (0%)3/8 (37.5%)8/8 (100%)
Module 1 Part B-1 Triple-negative Breast Cancer (TNBC) Expansion2/23 (8.7%)9/23 (39.1%)23/23 (100%)
Module 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) Expansion0/11 (0%)2/11 (18.2%)11/11 (100%)
Module 2 Part A CT7001 240mg OD + Fulvestrant (Cohort 1)0/6 (0%)2/6 (33.3%)6/6 (100%)
Module 2 Part A CT7001 360mg OD + Fulvestrant (Cohort 2)1/25 (4%)8/25 (32%)25/25 (100%)
Module 4 120mg OD Fed0/6 (0%)0/6 (0%)2/6 (33.3%)
Module 4 120mg OD Fasted0/8 (0%)0/8 (0%)7/8 (87.5%)
Module 4 360mg OD Fed0/7 (0%)0/7 (0%)5/7 (71.4%)
Module 4 360mg OD Fasted0/7 (0%)0/7 (0%)5/7 (71.4%)
Module 4 240mg OD Continuous Dosing0/8 (0%)0/8 (0%)8/8 (100%)
Module 4 360mg OD Continous Dosing1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240mg ODModule 1 Part A-Cohort 3 480mg ODModule 1 Part A-Cohort 4 360mg ODModule 1 Part A-Cohort 5 180mg BIDModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360mg OD + Fulvestrant (Cohort 2)Module 4 120mg OD FedModule 4 120mg OD FastedModule 4 360mg OD FedModule 4 360mg OD FastedModule 4 240mg OD Continuous DosingModule 4 360mg OD Continous Dosing
DiarrhoeaGastrointestinal disorders0/60/120/60/121/82/230/111/60/250/60/80/70/70/80/7
Atypical pneumoniaInfections and infestations0/60/120/60/120/80/230/111/60/250/60/80/70/70/80/7
BronchitisInfections and infestations1/60/120/60/120/80/230/110/60/250/60/80/70/70/80/7
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/61/120/60/120/80/230/110/60/250/60/80/70/70/80/7
Posterior reversible encephalopathy syndromeNervous system disorders0/60/120/60/120/80/230/111/60/250/60/80/70/70/80/7
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60/120/60/120/81/230/110/61/250/60/80/70/70/80/7
Lung disorderRespiratory, thoracic and mediastinal disorders1/60/120/60/120/80/230/110/60/250/60/80/70/70/80/7
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/60/121/60/120/80/230/110/60/250/60/80/70/70/80/7
NauseaGastrointestinal disorders0/60/120/60/120/80/230/110/60/250/60/80/70/70/81/7
Disease progressionGeneral disorders0/60/120/60/120/82/230/110/60/250/60/80/70/70/81/7
Most frequent other events
Showing 10 of 209
Most frequent other events
EventModule 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240mg ODModule 1 Part A-Cohort 3 480mg ODModule 1 Part A-Cohort 4 360mg ODModule 1 Part A-Cohort 5 180mg BIDModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360mg OD + Fulvestrant (Cohort 2)Module 4 120mg OD FedModule 4 120mg OD FastedModule 4 360mg OD FedModule 4 360mg OD FastedModule 4 240mg OD Continuous DosingModule 4 360mg OD Continous Dosing
DiarrhoeaGastrointestinal disorders6/68/126/612/125/821/2310/114/623/250/62/82/73/77/86/7
NauseaGastrointestinal disorders5/69/123/611/126/822/238/116/619/250/63/82/70/77/84/7
VomitingGastrointestinal disorders4/69/126/610/127/814/236/116/618/250/62/81/72/75/84/7
Upper respiratory tract infectionInfections and infestations5/61/120/62/121/82/231/110/60/250/60/80/70/72/80/7
FatigueGeneral disorders2/67/120/66/122/811/232/113/611/250/62/80/70/76/82/7
HeadacheNervous system disorders0/60/122/61/121/80/230/114/64/250/61/80/70/71/80/7
Decreased appetiteMetabolism and nutrition disorders1/62/121/63/121/83/236/112/611/250/61/81/70/73/82/7
Abdominal painGastrointestinal disorders3/61/122/65/121/86/232/111/67/250/60/80/70/71/81/7
ConstipationGastrointestinal disorders0/63/120/64/120/87/232/112/66/250/60/80/70/74/82/7
AnaemiaBlood and lymphatic system disorders1/65/121/62/121/81/233/111/63/250/60/80/70/70/81/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Module 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4-120 mg OD Fed-Fasted (Sequence 1)Module 4 120 mg OD Fasted-Fed (Sequence 2)Module 4 360 mg OD Fed-Fasted (Sequence 3)Module 4 360 mg OD Fasted-Fed (Sequence 4)Total
<=18 years0000000000000000
Between 18 and 65 years5463434195515122179
>=65 years130342246110322245
Sex: Female, Male
Sex: Female, Male(Participants)Module 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4-120 mg OD Fed-Fasted (Sequence 1)Module 4 120 mg OD Fasted-Fed (Sequence 2)Module 4 360 mg OD Fed-Fasted (Sequence 3)Module 4 360 mg OD Fasted-Fed (Sequence 4)Total
Female4263656230625022191
Male250320001100422233
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Module 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4-120 mg OD Fed-Fasted (Sequence 1)Module 4 120 mg OD Fasted-Fed (Sequence 2)Module 4 360 mg OD Fed-Fasted (Sequence 3)Module 4 360 mg OD Fasted-Fed (Sequence 4)Total
Hispanic or Latino0000000000200002
Not Hispanic or Latino45668551865214423102
Unknown or Not Reported22000015512002020
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Module 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4-120 mg OD Fed-Fasted (Sequence 1)Module 4 120 mg OD Fasted-Fed (Sequence 2)Module 4 360 mg OD Fed-Fasted (Sequence 3)Module 4 360 mg OD Fasted-Fed (Sequence 4)Total
American Indian or Alaska Native0000000000000000
Asian2000100000200005
Native Hawaiian or Other Pacific Islander0000000000000000
Black or African American0000000000200002
White45667561986204443107
More than one race02000004301000010
Unknown or Not Reported0000000000000000
Region of Enrollment
Region of Enrollment(participants)Module 1 Part A-Cohort 1 120mg ODModule 1 Part A-Cohort 2 240 mg ODModule 1 Part A-Cohort 3 480 mg ODModule 1 Part A-Cohort 4 360 mg ODModule 1 Part A-Cohort 5 180 mg BIDModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-240mgModule 1 Part A Paired Biopsy Breast Cancer Expansion Cohort-360mgModule 1 Part B-1 Triple-negative Breast Cancer (TNBC) ExpansionModule 1 Part B-2 Castrate Resistant Prostate Cancer (CRPC) ExpansionModule 2 Part A CT7001 240 mg OD + Fulvestrant (Cohort 1)Module 2 Part A CT7001 360 mg OD + Fulvestrant (Cohort 2)Module 4-120 mg OD Fed-Fasted (Sequence 1)Module 4 120 mg OD Fasted-Fed (Sequence 2)Module 4 360 mg OD Fed-Fasted (Sequence 3)Module 4 360 mg OD Fasted-Fed (Sequence 4)Total
United States000000000112000013
United Kingdom676685623115134443111
08

Study locations

23 sites
  • Research Site 54
    Tucson, Arizona 85719, United States
  • Research Site 31
    Beverly Hills, California 90211, United States
  • Research Site 37
    Tampa, Florida 33612, United States
  • Research Site 38
    Chicago, Illinois 60611, United States
  • Research Site 34
    Boston, Massachusetts 02215, United States
  • Research Site 47
    Cincinnati, Ohio 45236, United States
  • Research Site 39
    Columbus, Ohio 43212, United States
  • Research Site 36
    Portland, Oregon 97239, United States
  • Research Site 44
    Austin, Texas 78705, United States
  • Research Site 46
    Dallas, Texas 75246, United States
  • Research Site 48
    Salt Lake City, Utah 84112, United States
  • Research Site 33
    Salem, Virginia 24153, United States
  • Research site 11
    Brighton, BN2 5BE, United Kingdom
  • Research site 5
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site 7
    Glasgow, G12 0YN, United Kingdom
  • Research Site 10
    Liverpool, L69 3BX, United Kingdom
  • Research Site 9
    London, SE1 9RT, United Kingdom
  • Research Site 8
    London, W1G 6AD, United Kingdom
  • Research Site 3
    London, W2 1NY, United Kingdom
  • Research Site 1
    Manchester, M20 4BX, United Kingdom
  • Research Site 4
    Manchester, M20 4BX, United Kingdom
  • Research Site 2
    Oxford, OX3 7LE, United Kingdom
  • Research Site 6
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nat Commun. 2023 Jul 24;14(1):4444. doi: 10.1038/s41467-023-40061-y. PubMed 37488191 ↗
  • Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8. PubMed 32385714 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Dec 2022, 61 months.

Results were first posted in Jun 2026, 3 years 6 months after primary completion. A results delay was requested in Dec 2023.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 61 months is close to that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 6, 2017
StartActual
Nov 14, 2017
Primary completionActual
Dec 15, 2022
CompletionActual
Dec 15, 2022
Results delay requested
Dec 13, 2023
Results first posted
Jun 23, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03363893
Lead sponsor
Carrick Therapeutics Limited
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Nov 14, 2017
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022
Results posted
Jun 23, 2026
Last update
Jun 23, 2026

Study contacts

Matthew Krebs, MBChB PhD
principal investigator · The Christie Hospital, Manchester, UK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Samuraciclib

Start the discussion